Single-Domain Antibodies as Antibody-Drug Conjugates: From Promise to Practice-A Systematic Review.

ABSTRACT:

Background

Antibody-drug conjugates (ADCs) represent potent cancer therapies that deliver highly toxic drugs to tumor cells precisely, thus allowing for targeted treatment and significantly reducing off-target effects. Despite their effectiveness, ADCs can face limitations due to acquired resistance and potential side effects.

Objectives

This study focuses on advances in various ADC components to improve both the efficacy and safety of these agents, and includes the analysis of several novel ADC formats. This work assesses whether the unique features of VHHs-such as their small size, enhanced tissue penetration, stability, and cost-effectiveness-make them a viable alternative to conventional antibodies for ADCs and reviews their current status in ADC development.

Methods<

SUBMITTER: Medina Perez VM 

PROVIDER: S-EPMC11311928 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature